AMENDMENTS TO THE CLAIMS

The following Listing of the Claims replaces all prior claims in the application.

Claim 1 (Original). β -carboline derived guanidine alkaloid, tiruchenduramine of the Formula 1

1

isolated from an ascidian Synoicum macroglossum and its derivatives thereof.

Claim 2 (Original). A compound as claimed in claim 1 selected from the following:

1.
$$R_1=R_2=R_3=H$$
, $n=2$

2.
$$R_1=R_2=R_3=H$$
, $n=3$

3.
$$R_1=R_2=R_3=H$$
, $n=4$

4.
$$R_1=R_2=R_3=H$$
, $n=5$

5.
$$R_1=R_2=R_3=H$$
, $n=6$

6.
$$R_1=R_2=R_3=H$$
, $n=2$

7.
$$R_1 = R_2 = R_3 = H$$
, $n = 3$

8.
$$R_1=R_2=R_3=H$$
, $n=4$

9.
$$R_1=R_2=R_3=H$$
, $n=5$

10.
$$R_1=R_2=R_3=H$$
, $n=6$

$$R_1$$
 R_2
 R_3
 R_3
 R_3
 R_4
 R_4
 R_5
 R_4
 R_5
 R_5
 R_7
 R_7

1.
$$R_1$$
= Piperzine, R_2 = R_3 = H , n = 2

2.
$$R_1$$
= Piperzine, R_2 = R_3 = H , n = 3

3.
$$R_1$$
= Piperzine, R_2 = R_3 = H , n =4

4.
$$R_1$$
= Piperzine, R_2 = R_3 = H , n=5

5.
$$R_1$$
= Piperzine, R_2 = R_3 = H , n = 6

$$\begin{array}{c} R_1 \\ R_2 \\ R_3 \\ R_4 \\ \end{array}$$

1.
$$R_1$$
= Piperzine, R_2 = R_3 = H , n = 2

2.
$$R_1$$
= Piperzine, R_2 = R_3 = H , n = 3

3.
$$R_1$$
= Piperzine, R_2 = R_3 = H , n = 4

4.
$$R_1$$
= Piperzine, R_2 = R_3 = H , n = 5

5.
$$R_1$$
= Piperzine, R_2 = R_3 = H , n = 6

Serial No. 10/814,777 Preliminary Amendment Docket No. 03108/02001123-US0

Claim 3 (Original). A process for the preparation of β -carboline derived guanidine alkaloid tiruchenduramine of Formula 1

1

which comprises subjecting an ascidian to solvent extraction.

Claim 4 (Original). A process as in claim 3 wherein said ascidian is Synoicum macroglossum.

Claim 5 (Currently Amended). A process as claimed in claim 3 or 4 wherein said extraction comprises extraction in the presence of methanol followed by a dichloromethane:methanol extraction and the extract so obtained is subject to purification.

Claim 6 (Currently Amended). A process as claimed in claim 5 4 wherein said ascidian comprises freeze dried *Synoicum macroglossum*.

Claim 7 (Currently Amended). A process as claimed in claim 6 5 wherein said dichloromethane and methanol are used in a ratio of 1:1.

Claim 8 (Currently Amended). A process as claimed in claim 7 3 wherein after extraction with dichloromethane and methanol, the extract so obtained is partitioned between water and ethyl acetate EtOAc.

Claim 9 (Currently Amended). A process as claimed in claim 8 wherein said water extract is lypholized and and the residue is triturated with methanol MeOH.

Claim 10 (Currently Amended). A process as claimed in claim 5 to 9 wherein siad purification comprises a Sephadex LH-20 column chromatography.

Claim 11 (Currently Amended). A pharmaceutical composition comprising as an active ingredient a compound of Formula 1, and

1

along with a pharmaceutically acceptable carrier, vehicle or excipient.

Claim 12 (Currently Amended). A pharmaceutical composition comprising as an active ingredient a compound as claimed in claim 2 and alongwith a pharmaceutically acceptable carrier, vehicle or excipient.

Claim 13 (Currently Amended). A composition claimed in claim 11 or 12 wherein said composition is used for the treatment of diabetic disorders and wherein said active ingredient is present in an amount of about 78.8 µg.

Claim 14 (Original). A composition as claimed in claim 13 wherein the unit dosage of said composition is from about 15 mg to about 480 mg, preferably, from about 24 mg to about 280 mg.

Claim 15 (Currently Amended). A pharmaceutical composition comprising a first therapeutic agent consisting of a β -carboline derivative guanidine alkaloid, tiruchenduramine selected from the group consisting of compounds-sown in formulae 1 to through 20 and a second therapeutic agent different from said first therapeutic agent.

Claim 16 (Currently Amended). A composition as claimed in claim 15 wherein said second therapeutic agent is selected from alkylating agents, antimetabolites, vinca alkaloids, antibiotics, cytokines, growth factors and non-steroidal anti-inflammatory drugs, such as asprin.

Claim 17 (Currently Amended). Use of <u>a</u> β -carboline derivative guanidine alkaloid, tiruchenduramine <u>selected from the group consisting of compounds 1 through</u> <u>20 having a formula 1 to 20</u> in the treatment of diabetic disorders.

Claim 18 (Currently Amended). A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of \underline{a} β -carboline derivative guanidine alkaloid, tiruchenduramine selected from the group consisting of compounds 1 through 20 having the structure shown in formula 1 to 20.

Claim 19 (Currently Amended). A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 11 any one of claims 11 to 16.

Claim 20 (New). A composition as claimed in claim 13 wherein the unit dosage of said composition is from about 24 mg to about 280 mg.

Claim 21 (New). A composition claimed in claim 12 wherein said composition is used for the treatment of diabetic disorders and wherein said active ingredient is present in an amount of about $78.8 \mu g$.